Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention Results of the ISAR-ASPI Registry by Pulcinelli, Fabio M. et al.
J A C C V O L . 6 5 , N O . 1 9 , 2 0 1 5 Letters
M A Y 1 9 , 2 0 1 5 : 2 1 4 8 – 5 7
2153UL1TR000064). This work was supported by grants from the Gustavus and
Louis Pfeiffer Research Foundation; The Women’s Guild of Cedars-Sinai
Medical Center; The Ladies Hospital Aid Society of Western Pennsylvania;
QMED, Inc.; the Edythe L. Broad and the Constance Austin Women’s Heart
Research Fellowships, Cedars-Sinai Medical Center; the Barbra Streisand
Women’s Cardiovascular Research and Education Program, Cedars-Sinai
Medical Center; The Society for Women’s Health Research; and The Linda
Joy Pollin Women’s Heart Health Program and the Erika Glazer Women’s
Heart Health Project, Cedars-Sinai Medical Center. All other authors have
reported that they have no relationships relevant to the contents of this
paper to disclose.
RE F E RENCE S
1. Tivesten A, Vandenput L, Carlzon, et al. Dehydroepiandrosterone and its
sulfate predict the 5-year risk of coronary heart disease events in elderly men.
J Am Coll Cardiol 2014;64:1801–10.
2. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular
disease mortality in postmenopausal women: results from the National
Institutes of Health – National Heart, Lung, and Blood Institute (NHLBI)-S-
ponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol
Metab 2010;95:4985–92.
3. Bairey Merz CN. Sex, death, and the diagnosis gap. Circulation 2014;130:
740–2.
4. Bairey Merz CN, Regitz-Zagrosek Y. The case for sex- and gender-speciﬁc
medicine. JAMA Intern Med 2014;173:1348–9.
REPLY: Recognizing Sex Similaritiesin Cardiovascular Disease Research
Copper, Coronary Heart Disease,
and DehydroepiandrosteroneAspects of gender and biological sex are important to
address in research, and we thank Dr. Shufelt and
colleagues for their letter. Certainly it would have
been suitable to address the association between de-
hydroepiandrosterone (DHEA), its sulfate, and car-
diovascular risk in women in the discussion of our
paper (1), even if women were not included in
the MrOS cohort. The data by Shufelt et al. (2) are
interesting and suggest an association between low
DHEA-S and cardiovascular risk in women as in men,
whereas other studies have suggested a U-shaped
association in women (3).
We also thank Dr. Klevay for sharing his hypothesis
regarding copper, coronary heart disease, and DHEA,
proposing that low DHEA may be a sign of copper
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Aspirin Treatment and
Outcomes After
Percutaneous Coronary
InterventionResults of the ISAR-ASPI RegistryWe read with great interest the paper by Mayer et al.
(1) demonstrating an association between high
on-aspirin treatment platelet reactivity and cardio-
vascular complications in patients undergoing per-
cutaneous coronary intervention. We would like to
congratulate the investigators for this pivotal study
and suggest that they consider prior aspirin use as
another variable contributing to adverse outcomes. In
fact, we believe that the larger number of patients
with high on-aspirin treatment platelet reactivity in
the ISAR-ASPI (Intracoronary Stenting and Antith-
rombotic Regimen—Aspirin and Platelet Inhibition)
registry compared with other populations using tests
speciﬁc for COX-1 activity (2,3) may be due to the
higher percent of patients receiving aspirin treatment
at the time of hospital admission.
Such consideration follows our demonstration that
human megakaryocytes have an adaptive response to
aspirin, leading to up-regulation of platelet multidrug
resistance protein 4 (MRP4) (4). Aspirin effects are
reduced in patients undergoing coronary artery by-
pass grafting because of platelet MRP4 overex-
pression, because aspirin is an MRP4 substrate.
Moreover, with long-term drug exposure, eukaryotic
cells may trigger speciﬁc genes leading to cellular
mechanisms modulating their effects.
Because MRP4 inhibition reduces collagen-induced
platelet activation, we hypothesized that platelets
with MRP4 overexpression may be hyperresponsive.
A reduction of aspirin-dependent platelet inhibition
over time is well established. In fact, aspirin-treated
healthy volunteers, either at high (1,300 mg/day)
or low (100 mg/day) concentrations, showed reduced
platelet aggregation in the early weeks of treatment,
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7 to 8 weeks (5). We also demonstrated a progressive
reduction in platelet sensitivity to aspirin in long-
term aspirin-treated patients.
The genomic response to a pharmacological “chal-
lenge” with aspirin has also been demonstrated. After
aspirin administration, a set of platelet-enriched
genes and proteins associated with platelet function
and cardiovascular complications have been identi-
ﬁed. Moreover, increased platelet expression of
glycoprotein IIIa with aspirin treatment has been
demonstrated.
In conclusion, we suggest a better deﬁnition of the
impact of prior aspirin use, because the capability of
aspirin in changing protein platelet expression may
be useful to better understand high on-aspirin treat-
ment platelet reactivity.*Fabio M. Pulcinelli, MD
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REPLY: Aspirin Treatment and OutcomesAfter Percutaneous Coronary Intervention
Results of the ISAR-ASPI RegistryWe thank Dr. Pulcinelli and colleagues for their in-
terest in our publication (1). The high proportion of
patients (>90%) presenting on aspirin therapy in our
cohort likely would not enable a reliable analysis of
the role of the presence or absence of this therapy on
the platelet response to aspirin as measured in this
study.However, the fact that a signiﬁcantly lower pro-
portion of patients taking aspirin showed high on-
aspirin platelet reactivity (91.2% in patients with
vs. 93.8% in those without high on-aspirin platelet
reactivity; p ¼ 0.0006) does not support the authors’
hypothesis. In addition, as mentioned in the results
section of our paper (1), prior aspirin therapy was also
included in the multivariate model for the primary
outcome, the composite of death or stent thrombosis
at 1 year. From this model, prior aspirin therapy
was associated with an adjusted hazard ratio of 0.66
(95% conﬁdence interval: 0.45 to 0.96; p ¼ 0.03) for
the occurrence of the primary outcome, suggesting a
protective role against ischemic events.*Katharina Mayer, MD
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Coll Cardiol 2014;64:863–71.Does Size Matter?In Search of a Physiological Deﬁnition of
Myocardial AtrophyMechanical unloading using left ventricular assist
devices (LVADs) induces reverse remodeling of the
failing myocardium to levels that are possibly supe-
rior to any other strategy. However, evidence of a
